Cargando…
Pharmacokinetics and Endocrine Effects of an Oral Dose of D-Pinitol in Human Fasting Healthy Volunteers
The present study characterizes the oral pharmacokinetics of D-Pinitol, a natural insulin mimetic inositol, in human healthy volunteers (14 males and 11 females). D-Pinitol absorption was studied in (a) subjects receiving a single oral dose of 15 mg/kg (n = 10), or (b) 5 mg/kg pure D-Pinitol (n = 6)...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572189/ https://www.ncbi.nlm.nih.gov/pubmed/36235746 http://dx.doi.org/10.3390/nu14194094 |
_version_ | 1784810551225876480 |
---|---|
author | Navarro, Juan A. Díaz, Caridad Decara, Juan Medina-Vera, Dina Lopez-Gambero, Antonio J. Suarez, Juan Pavón, Francisco Javier Serrano, Antonia Vargas, Antonio Gavito, Ana Luisa Porras-Perales, Oscar Aranda, Jesús Vicente, Francisca Sanjuan, Carlos Baixeras, Elena de Fonseca, Fernando Rodríguez |
author_facet | Navarro, Juan A. Díaz, Caridad Decara, Juan Medina-Vera, Dina Lopez-Gambero, Antonio J. Suarez, Juan Pavón, Francisco Javier Serrano, Antonia Vargas, Antonio Gavito, Ana Luisa Porras-Perales, Oscar Aranda, Jesús Vicente, Francisca Sanjuan, Carlos Baixeras, Elena de Fonseca, Fernando Rodríguez |
author_sort | Navarro, Juan A. |
collection | PubMed |
description | The present study characterizes the oral pharmacokinetics of D-Pinitol, a natural insulin mimetic inositol, in human healthy volunteers (14 males and 11 females). D-Pinitol absorption was studied in (a) subjects receiving a single oral dose of 15 mg/kg (n = 10), or (b) 5 mg/kg pure D-Pinitol (n = 6), and (c) subjects receiving D-Pinitol as part of carbohydrate-containing carob pods-derived syrup with a 3.2% D-Pinitol (Dose of 1600 mg/subject, n = 9). The volunteers received a randomly assigned single dose of either D-Pinitol or carob pod-derived syrup. Blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 180, 240, 360 and 1440 min after intake. Plasma concentration of D-Pinitol was measured and pharmacokinetic parameters obtained. The data indicate that when given alone, the oral absorption of D-Pinitol is dose-dependent and of extended duration, with a Tmax reached after almost 4 h, and a half-life greater than 5 h. When the source of D-Pinitol was a carob pods-derived syrup, Cmax was reduced to 40% of the expected based on the data of D-Pinitol alone, suggesting a reduced absorption probably because of competition with monosaccharide transport. In this group, Tmax was reached before that of D-Pinitol alone, but the estimated half-life remained the same. In the D-Pinitol groups, plasma concentrations of glucose, insulin, glucagon, ghrelin, free fatty acids, and pituitary hormones were additionally measured. A dose of 15 mg/kg of D-Pinitol did not affect glucose levels in healthy volunteers, but reduced insulin and increased glucagon and ghrelin concentrations. D-Pinitol did not increase other hormones known to enhance plasma glucose, such as cortisol or GH, which were surprisingly reduced after the ingestion of this inositol. Other pituitary hormones (gonadotropins, prolactin, and thyroid-stimulating hormone) were not affected after D-Pinitol ingestion. In a conclusion, D-Pinitol is absorbed through the oral route, having an extended half-life and displaying the pharmacological profile of an endocrine pancreas protector, a pharmacological activity of potential interest for the treatment or prevention of insulin resistance-associated conditions. |
format | Online Article Text |
id | pubmed-9572189 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95721892022-10-17 Pharmacokinetics and Endocrine Effects of an Oral Dose of D-Pinitol in Human Fasting Healthy Volunteers Navarro, Juan A. Díaz, Caridad Decara, Juan Medina-Vera, Dina Lopez-Gambero, Antonio J. Suarez, Juan Pavón, Francisco Javier Serrano, Antonia Vargas, Antonio Gavito, Ana Luisa Porras-Perales, Oscar Aranda, Jesús Vicente, Francisca Sanjuan, Carlos Baixeras, Elena de Fonseca, Fernando Rodríguez Nutrients Article The present study characterizes the oral pharmacokinetics of D-Pinitol, a natural insulin mimetic inositol, in human healthy volunteers (14 males and 11 females). D-Pinitol absorption was studied in (a) subjects receiving a single oral dose of 15 mg/kg (n = 10), or (b) 5 mg/kg pure D-Pinitol (n = 6), and (c) subjects receiving D-Pinitol as part of carbohydrate-containing carob pods-derived syrup with a 3.2% D-Pinitol (Dose of 1600 mg/subject, n = 9). The volunteers received a randomly assigned single dose of either D-Pinitol or carob pod-derived syrup. Blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 180, 240, 360 and 1440 min after intake. Plasma concentration of D-Pinitol was measured and pharmacokinetic parameters obtained. The data indicate that when given alone, the oral absorption of D-Pinitol is dose-dependent and of extended duration, with a Tmax reached after almost 4 h, and a half-life greater than 5 h. When the source of D-Pinitol was a carob pods-derived syrup, Cmax was reduced to 40% of the expected based on the data of D-Pinitol alone, suggesting a reduced absorption probably because of competition with monosaccharide transport. In this group, Tmax was reached before that of D-Pinitol alone, but the estimated half-life remained the same. In the D-Pinitol groups, plasma concentrations of glucose, insulin, glucagon, ghrelin, free fatty acids, and pituitary hormones were additionally measured. A dose of 15 mg/kg of D-Pinitol did not affect glucose levels in healthy volunteers, but reduced insulin and increased glucagon and ghrelin concentrations. D-Pinitol did not increase other hormones known to enhance plasma glucose, such as cortisol or GH, which were surprisingly reduced after the ingestion of this inositol. Other pituitary hormones (gonadotropins, prolactin, and thyroid-stimulating hormone) were not affected after D-Pinitol ingestion. In a conclusion, D-Pinitol is absorbed through the oral route, having an extended half-life and displaying the pharmacological profile of an endocrine pancreas protector, a pharmacological activity of potential interest for the treatment or prevention of insulin resistance-associated conditions. MDPI 2022-10-01 /pmc/articles/PMC9572189/ /pubmed/36235746 http://dx.doi.org/10.3390/nu14194094 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Navarro, Juan A. Díaz, Caridad Decara, Juan Medina-Vera, Dina Lopez-Gambero, Antonio J. Suarez, Juan Pavón, Francisco Javier Serrano, Antonia Vargas, Antonio Gavito, Ana Luisa Porras-Perales, Oscar Aranda, Jesús Vicente, Francisca Sanjuan, Carlos Baixeras, Elena de Fonseca, Fernando Rodríguez Pharmacokinetics and Endocrine Effects of an Oral Dose of D-Pinitol in Human Fasting Healthy Volunteers |
title | Pharmacokinetics and Endocrine Effects of an Oral Dose of D-Pinitol in Human Fasting Healthy Volunteers |
title_full | Pharmacokinetics and Endocrine Effects of an Oral Dose of D-Pinitol in Human Fasting Healthy Volunteers |
title_fullStr | Pharmacokinetics and Endocrine Effects of an Oral Dose of D-Pinitol in Human Fasting Healthy Volunteers |
title_full_unstemmed | Pharmacokinetics and Endocrine Effects of an Oral Dose of D-Pinitol in Human Fasting Healthy Volunteers |
title_short | Pharmacokinetics and Endocrine Effects of an Oral Dose of D-Pinitol in Human Fasting Healthy Volunteers |
title_sort | pharmacokinetics and endocrine effects of an oral dose of d-pinitol in human fasting healthy volunteers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572189/ https://www.ncbi.nlm.nih.gov/pubmed/36235746 http://dx.doi.org/10.3390/nu14194094 |
work_keys_str_mv | AT navarrojuana pharmacokineticsandendocrineeffectsofanoraldoseofdpinitolinhumanfastinghealthyvolunteers AT diazcaridad pharmacokineticsandendocrineeffectsofanoraldoseofdpinitolinhumanfastinghealthyvolunteers AT decarajuan pharmacokineticsandendocrineeffectsofanoraldoseofdpinitolinhumanfastinghealthyvolunteers AT medinaveradina pharmacokineticsandendocrineeffectsofanoraldoseofdpinitolinhumanfastinghealthyvolunteers AT lopezgamberoantonioj pharmacokineticsandendocrineeffectsofanoraldoseofdpinitolinhumanfastinghealthyvolunteers AT suarezjuan pharmacokineticsandendocrineeffectsofanoraldoseofdpinitolinhumanfastinghealthyvolunteers AT pavonfranciscojavier pharmacokineticsandendocrineeffectsofanoraldoseofdpinitolinhumanfastinghealthyvolunteers AT serranoantonia pharmacokineticsandendocrineeffectsofanoraldoseofdpinitolinhumanfastinghealthyvolunteers AT vargasantonio pharmacokineticsandendocrineeffectsofanoraldoseofdpinitolinhumanfastinghealthyvolunteers AT gavitoanaluisa pharmacokineticsandendocrineeffectsofanoraldoseofdpinitolinhumanfastinghealthyvolunteers AT porrasperalesoscar pharmacokineticsandendocrineeffectsofanoraldoseofdpinitolinhumanfastinghealthyvolunteers AT arandajesus pharmacokineticsandendocrineeffectsofanoraldoseofdpinitolinhumanfastinghealthyvolunteers AT vicentefrancisca pharmacokineticsandendocrineeffectsofanoraldoseofdpinitolinhumanfastinghealthyvolunteers AT sanjuancarlos pharmacokineticsandendocrineeffectsofanoraldoseofdpinitolinhumanfastinghealthyvolunteers AT baixeraselena pharmacokineticsandendocrineeffectsofanoraldoseofdpinitolinhumanfastinghealthyvolunteers AT defonsecafernandorodriguez pharmacokineticsandendocrineeffectsofanoraldoseofdpinitolinhumanfastinghealthyvolunteers |